{"entity":{"id":"t-cypher-bio","kind":"company","name":"T-Cypher Bio","aka":["T-Cypher Bio Ltd","T-Cypher"],"tldr":"A small company near Oxford that designs medicines to point the immune system at new targets found only on diseased cells, for solid cancers and some autoimmune diseases.","summary":"T-Cypher Bio states that it develops immune-engaging medicines against novel disease-specific targets for cancer and autoimmune disease, with a pipeline across a range of solid tumours and selected autoimmune diseases, built on proprietary platforms that combine laboratory and computational methods (T-Cypher Bio website). Its registered address is Barton House, the Quadrant, Abingdon (T-Cypher Bio website). Its team page says that a number of inventions from the University of Oxford laboratory of its scientific co-founder have been licensed to the company (T-Cypher Bio, About us).","asOf":"2026-11-05","links":[{"label":"T-Cypher Bio website","url":"https://www.tcypherbio.com/"},{"label":"T-Cypher Bio, About us","url":"https://www.tcypherbio.com/about-us/"}],"tags":["immune-engager"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"hq":"Abingdon, Oxfordshire","country":"GB","companyType":"biotech","website":"https://www.tcypherbio.com","stage":"startup","investors":[],"funding":[]},"route":"/companies/t-cypher-bio/","neighbours":{"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}]}}